Please Wait
Applying Filters...
menu
    • menu
    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-03-23

    Virtual Booth

    An Enquiry

    Menu

    2803881-11-8

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Monte Rosa Therapeutics: Q4 & FY 2025 Results and Business Update
    Monte Rosa Therapeutics: Q4 & FY 2025 Results and Business Update

    17 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/17/3256993/0/en/Monte-Rosa-Therapeutics-Announces-Fourth-Quarter-and-Full-Year-2025-Financial-Results-and-Business-Updates.html

    GLOBENEWSWIRE
    17 Mar 2026
    Share Share
    Monte Rosa Therapeutics Secures Supply Deal For MRT-2359 Phase 2
    Monte Rosa Therapeutics Secures Supply Deal For MRT-2359 Phase 2

    16 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/16/3256118/0/en/Monte-Rosa-Therapeutics-Announces-Clinical-Supply-Agreement-to-Support-Phase-2-Trial-Evaluating-MRT-2359-in-Combination-with-Apalutamide-for-the-Treatment-of-Metastatic-Castration-.html

    GLOBENEWSWIRE
    16 Mar 2026
    Share Share
    Monte Rosa Therapeutics Updates MRT-2359 Data In Prostate Cancer
    Monte Rosa Therapeutics Updates MRT-2359 Data In Prostate Cancer

    24 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/24/3243353/0/en/Monte-Rosa-Therapeutics-Presents-Updated-Clinical-Data-from-Phase-1-2-Study-of-MRT-2359-in-Combination-with-Enzalutamide-in-Heavily-Pretreated-Metastatic-Castration-Resistant-Prost.html

    GLOBENEWSWIRE
    24 Feb 2026
    Share Share
    Monte Rosa Therapeutics Reports Strong Clinical Response
    Monte Rosa Therapeutics Reports Strong Clinical Response

    16 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/16/3206099/0/en/Monte-Rosa-Therapeutics-Announces-Compelling-Clinical-Activity-of-MRT-2359-in-Combination-with-Enzalutamide-in-Heavily-Pretreated-Metastatic-Castration-Resistant-Prostate-Cancer-Pa.html

    GLOBENEWSWIRE
    16 Dec 2025
    Share Share
    Monte Rosa Therapeutics To Unveil Latest MRT-2359 Study Results
    Monte Rosa Therapeutics To Unveil Latest MRT-2359 Study Results

    15 Dec 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/12/15/3205830/0/en/Monte-Rosa-Therapeutics-to-Present-Updated-MRT-2359-Phase-1-2-Study-Results.html

    GLOBENEWSWIRE
    15 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.